Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This document includes various patents and studies on innovations like a device for 3D monitoring of uterine activity, a bipolar forceps instrument, and nonpeptide oxytocin agonists, but reports no novel research findings.

This review discusses concerns about persistent side effects of finasteride, such as sexual dysfunction and suicidal ideation, urging the medical community to recognize and address these issues.

PFS affects some women, steroids easily bought online, hypogonadism info unreliable, low testosterone linked to CVD.

In this study, researchers found that the number of dermal papilla cells in hair follicles determines hair size and shape in mice, suggesting potential avenues for addressing hair loss.

This study presents a validated HPTLC method for simultaneously determining five BPH drugs, showing high sensitivity and selectivity for potential use in quality-control analysis.

This case report describes a 39-year-old woman whose dermatomyositis-systemic lupus erythematosus overlap syndrome symptoms resolved after switching to tofacitinib.

This study highlights the interconnected emotional distress between patients with end-stage COPD and their family caregivers, emphasizing that both parties' functional and emotional variables influence each other's distress.

In this study, researchers found that two dominant haplotypes in the EDA2R/AR intergenic region have likely been shaped by demographic changes and selection during human evolution, particularly notable in African and non-African populations.

In this murine study, researchers found that topical treatment with Philippine stingless bee propolis increased folliculogenesis, epidermal thickness, and melanogenesis, but not hair length, potentially supporting hair follicle regeneration and melanocyte function in chemotherapy-induced alopecia models.

In this study, researchers observed that individuals with alopecia areata exhibited significant changes in scalp microbiota diversity and composition, which were linked to disease severity and inflammation markers, though it remains unclear if these microbial shifts are a cause or a result of hair loss.

Pharmacists play a crucial role in patient care and education.

This study examined the demographics of patients diagnosed with pernio and compared their vitamin B12, folate, and ferritin levels with those of a control group.

This study suggests that the adrenal gland may contribute to prostate cancer treatment resistance and indicates potential steroid production or dependency in ovarian cancer.

This study found that gels containing glycyrrhizic acid and aqueous Glycyrrhiza glabra extract significantly reduced underarm hair growth in terms of area, thickness, length, and number compared to their gel bases.

This study showed that regulation of adipose androgen generation via AKR1C3 may contribute to a cycle of hyperinsulinaemia and lipid accumulation in women with PCOS.

This study observed that reduced in utero exposure to the neurosteroid allopregnanolone increased anxiety-like behavior in female guinea pigs during the juvenile period without affecting long-term allopregnanolone levels.

In this study, UPA at doses of 15 mg and 30 mg showed higher efficacy than placebo for treating severe alopecia areata in adults and adolescents over 24 weeks, with a safety profile similar to approved uses.

Dutasteride effectively treats benign prostatic hyperplasia, improving symptoms and quality of life.

In this case report, researchers observed that a 35-year-old male with alopecia universalis achieved full regrowth of scalp, eyebrow, and facial hair with oral upadacitinib treatment after previous therapies failed to provide lasting relief.

This review discusses recent advancements in understanding the use of 5 alpha-reductase inhibitors for benign prostatic hyperplasia, indicating that dual isoenzyme inhibitors like dutasteride may enhance treatment outcomes, but no new clinical results are presented.

This retrospective pharmacovigilance study reviewed adverse event reports from 2004 to 2025 for drugs treating benign prostatic hyperplasia, identifying distinct safety signals for α1-blockers, 5ARIs, and PDE5I, including some potential new adverse events that require further investigation.

This review suggests that excessive facial photoprotection could play a role in frontal fibrosing alopecia through a disturbance in immunological balance via the aryl hydrocarbon receptor-kynurenine pathway.

This letter discusses the use of UVA-1 in the treatment of alopecia areata but reports no new clinical results.

This review found an increasing trend in research on sperm DNA fragmentation over the past 20 years, especially focusing on lifestyle factors, asthenozoospermia, and varicocele, with the TUNEL technique as a predominant method.

This review discusses the pharmacologic effects, safety, and efficacy of dutasteride and finasteride for BPH, finding similar clinical benefits but greater DHT reduction with dutasteride and reports no new trial results.

This review discusses hormonal control and treatment options for benign prostatic hyperplasia, highlighting similar efficacy and safety between finasteride and dutasteride, and reports no clinical results; further studies are suggested for new therapeutic agents.

This research identified 18 significant SNPs and several candidate genes associated with udder conformation traits in Holstein cattle, providing insights into their genetic architecture.

This study highlights the recent FDA approval of baricitinib as the first on-label treatment for severe alopecia areata, whereas previous treatments were off-label therapies like systemic steroids and immunosuppressants.

In this study, daily treatment with ritlecitinib for up to 24 months led to significant reductions in high-severity alopecia areata SALT scores among patients aged ≥12 years, including those with severe forms such as alopecia totalis and universalis.

This study found that IsoPSA's ability to detect both any prostate cancer and clinically actionable prostate cancer remains unaffected by medications like 5-ARIs and α-blockers, which are commonly used to treat benign prostatic hyperplasia symptoms.